I'm not listening in but have scanned the evidence review briefly, and am generally pleasantly surprised. Glad to see Rituximab mentioned several times, and the flaws of PACE included....
I have not scanned the FINAL report yet but I can tell you that there was a LOT of action behind the scenes from patients, clinicians, advocates, and researchers to assure that Rituximab was mentioned as well as the flaws of PACE. Many people sent e-mails during the AHRQ evidence review draft comment period and I hope that had some impact on the review.
If you like that Rituximab and the flaws of PACE was mentioned, tell the powers that me that you liked that part. There is one month after the NIH P2P report during which the public can comment. I don't think the link is published yet as the report is not out but look for it.
Given the poor energy levels I have, like the rest of you, one lesson I have learned over time is to voice my concerns not just with sympathetic people, like on this forum, but at the people who need to hear it.